News | June 01, 2022
NATCO launches first generic version of Nexavar Tablets in the US
The product will be launched by NATCO's commercial partner Viatris.
The product will be launched by NATCO's commercial partner Viatris.
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
The ABDM public dashboard is a one-stop solution for information on the mission’s progress up to state/UT level
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The integration and transition of the brands are expected to be completed by June 2022.
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
Subscribe To Our Newsletter & Stay Updated
